Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.
about
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic ImplicationsNeural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)Silent latency periods in methylmercury poisoning and in neurodegenerative diseaseNeural repair in the adult brainCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersGSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synucleinPharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesStriatal neuroinflammation promotes Parkinsonism in ratsEnhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SActivation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.Microstimulation of the human substantia nigra alters reinforcement learningMotivational systems in adolescence: possible implications for age differences in substance abuse and other risk-taking behaviors.Proximity of Substantia Nigra Microstimulation to Putative GABAergic Neurons Predicts Modulation of Human Reinforcement LearningThe synaptic framework for chemical signaling in nucleus accumbens.Pharmacotherapy for advanced Parkinson's disease.Immunocytochemical localization of the dopamine transporter in human brain.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Electrophysiological evidence for functionally distinct neuronal populations in the human substantia nigra.Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet.Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET studyCognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's diseaseA single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's diseaseOn the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?Do dopamine agonists or levodopa modify Parkinson's disease progression?Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's diseaseFunctional reorganization of the presynaptic dopaminergic terminal in parkinsonism.[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseasePost-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease modelsIncreased latencies to initiate cocaine self-administration following laterodorsal tegmental nucleus lesions.Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.Feeding behavior in dopamine-deficient mice.Brain-derived neurotrophic factor increases the electrical activity of pars compacta dopamine neurons in vivo.
P2860
Q21129423-5BCFE5F9-B60F-4CB8-97DE-16D31EBC64FAQ24619949-0CF1D977-4B2B-43CF-8299-DF0A651647AFQ24812630-F8FECC77-A55C-4592-9222-DF18AB2A7045Q26766133-971B3BC7-F2BD-4415-9AE9-57C0F1674CD1Q26826093-607E0114-22FA-42F8-81F0-C31E4CF2D2CFQ27331743-CF67B699-7B25-4C73-8CBF-C01DAB547626Q28088705-8B2E84D5-A243-4FA4-B05A-8B86E5F6C5E8Q28475466-7A7413CA-3BC9-40AA-8E94-87E2D5D49DF7Q28589899-13052B1F-196A-4ED3-8ECC-F621DB019A20Q32134305-7BCC9899-0CE4-4B26-A407-CC5FDCEF64D9Q33255884-200CE5C4-6B8F-4F83-A585-39F2DF74BFFEQ33557483-DF4182F1-85DC-438E-B0CD-FF6A2B5F402CQ33605783-4CEE2D56-E576-40A9-BAF1-06C42289AC0BQ33624258-C9B377D6-3CD4-482B-84D6-8B56628CABA5Q33650033-95CC31F4-7D58-4A61-A139-7EC8CF6EDE1DQ33692754-ACCD7399-7CDB-49B2-8C7A-FE601987917AQ33821336-36270C54-A935-47E3-84D6-3059CD286720Q33864441-8D98E220-5836-407F-A3A7-F38ECA8A7CF8Q34094008-4A684A0A-1B3A-437E-974C-6198160E10B1Q34153959-63E05FEE-764A-44E0-8D44-5B42ADDBF739Q34212422-2EFD6CBE-3B87-4635-9A91-AC05F15BEAFBQ34258319-A7DE31D6-5C0F-434C-8A0C-DF9AA16A116FQ34258327-01D9DFD9-C672-404C-9EAD-BB09AE1D53CDQ34307633-445B933C-D8EC-4851-8D5D-7653396F4C8FQ34309950-0FD71DE9-D519-4DAE-AC1F-A04C85D02A9CQ34314213-379FD195-F0B2-4A9F-AA7D-4D64E9AE12D3Q34565712-CE4E313F-8F97-4946-8D05-A67D43849519Q34682391-B2026E99-A910-4362-9B54-3D6964B5161DQ34794235-D0E1CB2F-30B5-4668-81B6-92AD8E8996AFQ35015794-183C7108-EAA6-4854-A51A-F7F641EFE504Q35054558-4EDD2788-D9DC-4E5B-9F1E-10E04792C3DCQ35097046-840464A8-D8AF-4C02-A82A-C497E5BB3EB9Q35157431-C029B777-D2F4-4FF5-941B-6BDA7D6A0F3AQ35209394-31B4C758-A2B2-42D9-BB7F-2C4BAD307AD7Q35471953-41A12995-FE39-41B5-A1D2-3B8C1DFA6586Q35529695-928212DD-056B-43D9-AC0E-2AD2B47F33B7Q35582205-900B0D6E-EF76-4040-B209-8FE053DCE05CQ35690133-0AF0755C-E586-4C1C-AA1A-ACB3C2D643F4Q35735190-9A4595AA-8190-49EA-8436-E2A7807819C4Q35754302-E0B9C3A6-B7B2-4567-9B06-900DD8CD1AD6
P2860
Compensations after lesions of central dopaminergic neurons: some clinical and basic implications.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Compensations after lesions of ...... inical and basic implications.
@ast
Compensations after lesions of ...... inical and basic implications.
@en
type
label
Compensations after lesions of ...... inical and basic implications.
@ast
Compensations after lesions of ...... inical and basic implications.
@en
prefLabel
Compensations after lesions of ...... inical and basic implications.
@ast
Compensations after lesions of ...... inical and basic implications.
@en
P2093
P1476
Compensations after lesions of ...... inical and basic implications.
@en
P2093
Abercrombie ED
Stricker EM
Zigmond MJ
P304
P356
10.1016/0166-2236(90)90112-N
P577
1990-07-01T00:00:00Z